U.S. market Closed. Opens in 11 hours 21 minutes

ZVSA | ZyVersa Therapeutics, Inc. Stock Financials Income Statements Annual

(Stock Exchange: NASDAQ)
*Sign In to persist settings
Financial Year End2023-12-312022-12-312021-12-312020-12-31
RevenueN/AN/AN/AN/A
Cost of Revenue10.40K10.40K10.40K10.40K
Gross Profit-10.40K-10.40K-10.40K-10.40K
Operating Expenses14.41M13.01M7.70M11.83M
Selling, General & Admin11.20M7.61M5.58M5.36M
Research & Development3.21M5.41M2.12M6.47M
Other Operating Expenses93.33BN/AN/AN/A
Operating Income-14.42M-13.01M-7.70M-11.83M
Other Expenses / Income-93.33M-1.03M-379.79K-850.11K
Before Tax Income-107.75M-14.05M-8.08M-12.68M
Income Tax Expenses-9.46M745.05M821.37K516.45K
Net Income-98.30M-759.10M-8.91M-13.20M
Interest Expenses-457.00K427.54K821.37K516.45K
Basic Shares Outstanding97.50K259.48K465.53K465.53K
Diluted Shares Outstanding97.50K259.48K465.53K465.53K
EBITDA-14.41M-13.00M-7.69M-11.82M
EBITDA Margin0.00%0.00%0.00%0.00%
EBIT-108.21M-13.62M-7.26M-12.17M
EBIT Margin0.00%0.00%0.00%0.00%
Financial Year End2023-12-312022-12-312021-12-312020-12-31
An error has occurred. This application may no longer respond until reloaded. Reload 🗙